| Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization AR Pombo Antunes, I Scheyltjens, F Lodi, J Messiaen, A Antoranz, ... Nature neuroscience 24 (4), 595-610, 2021 | 440 | 2021 |
| Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies AR Pombo Antunes, I Scheyltjens, J Duerinck, B Neyns, K Movahedi, ... Elife 9, e52176, 2020 | 236 | 2020 |
| Phase II study of sunitinib malate in patients with recurrent high-grade glioma B Neyns, J Sadones, C Chaskis, M Dujardin, H Everaert, S Lv, J Duerinck, ... Journal of neuro-oncology 103, 491-501, 2011 | 168 | 2011 |
| Augmenting Microsoft's HoloLens with vuforia tracking for neuronavigation T Frantz, B Jansen, J Duerinck, J Vandemeulebroucke Healthcare technology letters 5 (5), 221-225, 2018 | 159 | 2018 |
| Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial J Duerinck, JK Schwarze, G Awada, J Tijtgat, F Vaeyens, C Bertels, ... Journal for immunotherapy of cancer 9 (6), 2021 | 81 | 2021 |
| Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal … S Lv, E Teugels, J Sadones, S De Brakeleer, J Duerinck, SDU FOUR, ... International journal of oncology 41 (3), 1029-1035, 2012 | 80 | 2012 |
| Systematic review of current randomised control trials in chronic subdural haematoma and proposal for an international collaborative approach E Edlmann, DC Holl, HF Lingsma, J Bartek, A Bartley, J Duerinck, ... Acta neurochirurgica 162, 763-776, 2020 | 79 | 2020 |
| Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma J Duerinck, S Du Four, F Bouttens, C Andre, V Verschaeve, ... Journal of neuro-oncology 136, 115-125, 2018 | 71 | 2018 |
| Mini-craniotomy as the primary surgical intervention for the treatment of chronic subdural hematoma—a retrospective analysis J Van Der Veken, J Duerinck, R Buyl, K Van Rompaey, P Herregodts, ... Acta neurochirurgica 156, 981-987, 2014 | 68 | 2014 |
| Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma J Duerinck, S Du Four, F Vandervorst, N D’Haene, M Le Mercier, ... Journal of neuro-oncology 128, 147-155, 2016 | 56 | 2016 |
| Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies S Du Four, S Wilgenhof, J Duerinck, A Michotte, A Van Binst, M De Ridder, ... European journal of cancer 48 (16), 3045-3051, 2012 | 54 | 2012 |
| The effect of augmented reality on the accuracy and learning curve of external ventricular drain placement F Van Gestel, T Frantz, C Vannerom, A Verhellen, AG Gallagher, ... Neurosurgical focus 51 (2), E8, 2021 | 53 | 2021 |
| Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx) G Awada, LB Salama, J De Cremer, JK Schwarze, L Fischbuch, ... Journal for immunotherapy of cancer 8 (2), 2020 | 46 | 2020 |
| Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients S Du Four, A Hong, M Chan, M Charakidis, J Duerinck, S Wilgenhof, ... Case reports in oncological medicine 2014 (1), 417913, 2014 | 45 | 2014 |
| Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion S Du Four, SK Maenhout, D Benteyn, B De Keersmaecker, J Duerinck, ... Cancer Immunology, Immunotherapy 65, 727-740, 2016 | 42 | 2016 |
| Randomized trial comparing burr hole craniostomy, minicraniotomy, and twist drill craniostomy for treatment of chronic subdural hematoma J Duerinck, J Van Der Veken, S Schuind, F Van Calenbergh, J van Loon, ... Neurosurgery 91 (2), 304-311, 2022 | 37 | 2022 |
| Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab S Du Four, Y Janssen, A Michotte, AM Van Binst, R Van den Begin, ... Cancer Medicine 7 (10), 4870-4879, 2018 | 26 | 2018 |
| GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide S Parik, J Fernández-García, F Lodi, K De Vlaminck, M Derweduwe, ... Frontiers in oncology 12, 988872, 2022 | 23 | 2022 |
| Neuro-oncological augmented reality planning for intracranial tumor resection F Van Gestel, T Frantz, F Buyck, W Geens, Q Neuville, M Bruneau, ... Frontiers in Neurology 14, 1104571, 2023 | 19 | 2023 |
| Expression of thyroid transcription factor 1 in a chordoid glioma A Michotte, J Van Der Veken, M Huylebrouck, J Duerinck, J D'Haens, ... Journal of the Neurological Sciences 346 (1), 362-363, 2014 | 16 | 2014 |
Bart NeynsDiensthoofd, Medische Oncologie, Universitair Ziekenhuis BrusselVerified email at uzbrussel.be